Kinetic response of wild and mutant core codon 70 strains of HCV genotype 1b to pegylated interferon-α and ribavirin therapy

被引:2
|
作者
Hu, Zhongjie [1 ]
Liu, Ying [2 ]
Qiu, Lixia [1 ]
Fan, Zuopeng [1 ]
Nie, Wei [1 ]
Liang, Shan [1 ]
Jin, Ronghua [3 ]
机构
[1] Capital Med Univ, Beijing Youan Hosp, Dept Hepatitis & Tox Liver Dis C, Beijing 100069, Peoples R China
[2] Capital Med Univ, Beijing Youan Hosp, Management Ctr Med Record, Beijing 100069, Peoples R China
[3] Capital Med Univ, Beijing Youan Hosp, Beijing 100069, Peoples R China
关键词
Hepatitis C virus; Genotype; 1b; Amino acid 70 substitution; Interferon; Viral kinetics; HEPATITIS-C VIRUS; AMINO-ACID SUBSTITUTIONS; VIROLOGICAL RESPONSE; JAPANESE PATIENTS; COMBINATION THERAPY; INHIBITS INTERFERON; PREDICTIVE FACTORS; GENETIC-VARIATION; NON-A; PROTEIN;
D O I
10.1186/s12985-015-0451-9
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Background: Amino acid (aa) 70 substitution (R70Q/H) in the core protein of hepatitis C virus (HCV) genotype 1b has been shown to be one of the key factors in determining resistance for pegylated interferon-alpha plus ribavirin combination therapy (PEG-IFN alpha/RBV). But the exact mechanisms remain unclear. The aim of this study was to investigate the dynamic response of wild and mutant core codon 70 strains to PEG-IFN alpha/RBV treatment. Methods: One hundred twelve Chinese patients with chronic HCV 1b infection were enrolled and received a standard protocol of 48 weeks of PEG-IFN alpha/RBV therapy and 24 consecutive weeks of follow-up. Serial blood samples were obtained at pretreatment baseline, and again at weeks 2, 4, 8, 12, and 24 during therapy for the quantification of 70R and 70Q/H strains. Dynamic characteristics and association with early virological response (EVR), sustained virological response (SVR) and IL28B genotypes were analyzed. Results: Of the 112 patients enrolled in this study, 93.8 % (105/112) were infected with mixture of 70R and 70Q/H strains before treatment. The 70Q/H strain was dominant in 20.5 % of patients. 42.9 % of patients with dominant 70Q/H exhibited EVR versus 88.6 % of patients with dominant 70R (P < 0.001). Furthermore, 35.0 % of patients with dominant 70Q/H exhibited SVR versus 77.4 % with dominant 70R (P < 0.001). However, regardless of the dominant strain, virological response types or the IL28B SNP genotypes, 70Q/H strains always exhibited the same response to treatment as the 70R strains and the percentage of HCV harboring the 70Q/H substitution did not change significantly during treatment. Conclusions: Although the ratio of 70Q/H to 70R is related to the virological response, 70Q/H strains always exhibited the same response as the 70R strains during PEG-IFN alpha/RBV treatment. Substitution of R70Q/H alone is not enough to lead to resistance to therapy. Positive selection for 70Q/H induced by IFN alpha was not observed.
引用
收藏
页数:10
相关论文
共 50 条
  • [21] RESPONSE FACTORS TO PEGYLATED INTERFERON-ALFA/RIBAVIRIN TREATMENT IN CHRONIC HEPATITIS C PATIENTS GENOTYPE 1B
    Jovanovic-Cupic, Snezana
    Glisic, S.
    Stanojevic, M.
    Vasiljevic, N.
    Bojic-Milinovic, T.
    Bozovic, A.
    Dimitrijevic, B.
    ARCHIVES OF BIOLOGICAL SCIENCES, 2014, 66 (01) : 193 - 201
  • [22] Antiviral response of HCV genotype-1 to consensus interferon and ribavirin compared with pegylated interferon and ribavirin. A preliminary report.
    Sjogren, MH
    Sjogren, R
    Lyons, MF
    Ryan, M
    Santoro, J
    Smith, C
    Reddy, KR
    Bonkovsky, H
    Huntley, B
    Ibarra, L
    Faris-Young, S
    HEPATOLOGY, 2004, 40 (04) : 396A - 397A
  • [23] Short-term prolongation of pegylated interferon and ribavirin therapy for genotype 1b chronic hepatitis C patients with early viral response
    Ikeda, Hiroki
    Suzuki, Michihiro
    Okuse, Chiaki
    Yamada, Norie
    Okamoto, Masaru
    Kobayashi, Minoru
    Nagase, Yoshihiko
    Takahashi, Hideaki
    Matsunaga, Koutarou
    Matsumoto, Nobuyuki
    Itoh, Fumio
    Yotsuyanagi, Hiroshi
    Koitabashi, Yu
    Yasuda, Kiyomi
    Iino, Shiro
    HEPATOLOGY RESEARCH, 2009, 39 (08) : 753 - 759
  • [24] Impact of mutation in HCV ISDR on the efficacy of the combined pegylated interferon/ribavirin therapy in Chinese patients with chronic hepatitis C virus genotype 1b infection
    Li, J. T.
    Wei, J. F.
    Zhou, Y. P.
    Li, W.
    Zeng, Y. L.
    Wang, J. J.
    Zhou, B.
    Liu, S. W.
    Wu, Y. S.
    Hou, J. L.
    INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, 2011, 15 : S16 - S16
  • [25] THE ROLE OF SUBSTITUTIONS IN THE CORE AND NS5A REGION OF HEPATITIS C VIRUS GENOTYPE 1B ON RESPONSIVENESS TO PEGYLATED INTERFERON AND RIBAVIRIN COMBINATION THERAPY
    Katano, Y.
    Ishigami, M.
    Nakano, I.
    Hayashi, K.
    Honda, T.
    Goto, H.
    JOURNAL OF HEPATOLOGY, 2009, 50 : S228 - S228
  • [26] Triple (interferon, ribavirin, amantadine) versus double (interferon, ribavirin) re-therapy for interferon relapser genotype 1b HCV chronic active hepatitis patients
    Piai, G
    Rocco, P
    Tartaglione, MT
    Ciarleglio, A
    Focareta, R
    Grimaldi, E
    Ievoli, F
    Iuliano, D
    Pacelli, M
    Forte, G
    HEPATOLOGY RESEARCH, 2003, 25 (04) : 355 - 363
  • [27] Contribution of ribavirin transporter gene polymorphism to treatment response in peginterferon plus ribavirin therapy for HCV genotype 1b patients
    Tsubota, Akihito
    Shimada, Noritomo
    Yoshizawa, Kai
    Furihata, Tomomi
    Agata, Rie
    Yumoto, Yoko
    Abe, Hiroshi
    Ika, Makiko
    Namiki, Yoshihisa
    Chiba, Kan
    Fujise, Kiyotaka
    Tada, Norio
    Aizawa, Yoshio
    LIVER INTERNATIONAL, 2012, 32 (05) : 826 - 836
  • [28] MUTATIONS IN THE CORE AND NS5A REGION OF HEPATITIS C VIRUS GENOTYPE 1B AND CORRELATION WITH RESPONSE TO PEGYLATED-INTERFERON-ALPHA 2B AND RIBAVIRIN COMBINATION THERAPY
    Hayashi, Kazuhiko
    Katano, Yoshiaki
    Ishigami, Masatoshi
    Nakano, Isao
    Goto, Hidemi
    Toyoda, Hidenori
    Kumada, Takashi
    HEPATOLOGY, 2008, 48 (04) : 848A - 849A
  • [29] Mutations in the core and NS5A region of hepatitis C virus genotype 1b and correlation with response to pegylated-interferon-alpha 2b and ribavirin combination therapy
    Hayashi, K.
    Katano, Y.
    Ishigami, M.
    Itoh, A.
    Hirooka, Y.
    Nakano, I.
    Urano, F.
    Yoshioka, K.
    Toyoda, H.
    Kumada, T.
    Goto, H.
    JOURNAL OF VIRAL HEPATITIS, 2011, 18 (04) : 280 - 286
  • [30] Amino acid substitutions in core region of hepatitis C virus genotype 1b predict poor response to pegylated-interferon-alpha 2b and ribavirin combination therapy
    Hayashi, Kazuhiko
    Katano, Yoshiaki
    Honda, Takashi
    Nakano, Isac
    Kumada, Takashi
    Goto, Hiderm
    GASTROENTEROLOGY, 2008, 134 (04) : A772 - A772